CRDF - Cardiff Oncology, Inc.

-

$undefined

N/A

(N/A)

Cardiff Oncology, Inc. NasdaqCM:CRDF Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies for the treatment of various cancers. Its lead drug candidate is Onvansertib, an oral and selective polo-like kinase 1 inhibitor for treating RAS-mutated metastatic colorectal cancer. The company also focuses on the clinical program in indications, such as investigator-initiated ongoing or planned trials in metastatic pancreatic ductal adenocarcinoma, small cell lung cancer, and triple negative breast cancer; CRDF-004, a Phase 2 open-label randomized multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab or SoC FOLFOX and bevacizumab for the first-line treatment of patients with RAS-mutated mCRC; TROV-054, a Phase 1b/2 open-label multi-center clinical trial of onvansertib in combination with SoC FOLFIRI and bevacizumab for the second-line treatment of patients with KRAS-mutated mCRC; and CRDF-001, a Phase 2 open-label multi-center clinical trial of onvansertib in combination with nanoliposomal irinotecan leucovorin, and fluorouracil for second line treatment of patients with mPDAC. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was founded in 1999 and is headquartered in San Diego, California.

Location: 11055 Flintkote Avenue, San Diego, CA, 92121, United States | Website: https://www.cardiffoncology.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

143.7M

Cash

79.89M

Avg Qtr Burn

-10.69M

Short % of Float

29.30%

Insider Ownership

5.64%

Institutional Own.

45.30%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Onvansertib (monotherapy) Details
Cancer, Small cell lung cancer

Phase 2

Data readout

Onvansertib + SOC (FOLFIRI + bevacizumab or FOLFOX + bevacizumab) Details
Metastatic colorectal cancer

Big Mover™

Susp. Mover™

Phase 2

Data readout

Onvansertib + Zytiga (abiraterone) Details
Prostate cancer, Cancer, Castration-resistant prostate cancer

Phase 2

Update

Phase 2

Update

Onvansertib + Paclitaxel Details
Cancer, Triple-negative breast cancer

Phase 1/2

Update

Failed

Discontinued

Onvansertib + decitabine Details
Cancer, Acute myeloid leukemia

Failed

Discontinued